{"id":"d9c199be1667","type":"article","url":"https://hartvaat.nl/2026/01/20/voorspelling-van-individuele-corticosteroidrespons-bij-iga-nefropathie-testing-t/","title":"Voorspelling van individuele corticosteroïdrespons bij IgA-nefropathie (TESTING-trial)","title_en":"A secondary analysis of the TESTING trial predicted individual patient response to corticosteroid treatment in IgA nephropathy","category":"chronische nierziekte","category_label":"Nierziekte","professions":["apotheker","internist"],"tags":["iaso-dcm"],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(26)00005-0/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(26)00005-0/fulltext","authors":["Mark Canney","Sana Shan","Lee Er","Laurent Billot","Jialin Han","Muh Geot Wong","Helen Monaghan","Michelle Hladunewich","Lai Seong Hooi","Vivek Jha","Jicheng Lv","Vlado Perkovic","Hong Zhang","Daniel C. Cattran","Sean J. Barbour","TESTING trial steering committee"],"significance":5,"published":"2026-01-20","source_date":"2026-01-20","image":"","kennis":[],"congress":"","summary_en":"A secondary analysis of the TESTING trial developed a prediction model for individual patient response to corticosteroid treatment in IgA nephropathy, enabling more targeted use of immunosuppression while minimising adverse effects.","created":"2026-07-03T10:25:32Z","updated":"2026-07-03T13:24:56Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Corticosteroïden zijn effectief bij IgA-nefropathie maar hebben belangrijke bijwerkingen. In deze secundaire analyse van de TESTING-trial werd een model ontwikkeld om de individuele respons op corticosteroïdbehandeling te voorspellen.","abstract_original":"Corticosteroids are effective for treating IgA nephropathy but have important adverse effects. In this secondary analysis of the TESTING cohort, we generated a model to predict, for an individual patient, the probability that they will respond to corticosteroids."}